These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 8033152

  • 1. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Børresen AL, Cornelisse CJ, Devilee P.
    Cancer Res; 1994 Aug 01; 54(15):4200-6. PubMed ID: 8033152
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
    Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH, Ali IU.
    Cancer Res; 1992 Dec 01; 52(23):6716-21. PubMed ID: 1358438
    [Abstract] [Full Text] [Related]

  • 4. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G, Barkardottir RB, Agnarsson BA, Johannesdottir G, Olafsdottir K, Egilsson V, Ingvarsson S.
    Oncogene; 1998 Jan 08; 16(1):21-6. PubMed ID: 9467939
    [Abstract] [Full Text] [Related]

  • 5. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA, Zhuang Z, Man Y, Park WS, Emmert-Buck M, Tavassoli FA.
    Mod Pathol; 1999 Dec 08; 12(12):1083-9. PubMed ID: 10619258
    [Abstract] [Full Text] [Related]

  • 6. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.
    Nishida N, Fukuda Y, Kokuryu H, Toguchida J, Yandell DW, Ikenega M, Imura H, Ishizaki K.
    Cancer Res; 1993 Jan 15; 53(2):368-72. PubMed ID: 8093350
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN.
    Mol Carcinog; 2002 Jun 15; 34(2):78-90. PubMed ID: 12112314
    [Abstract] [Full Text] [Related]

  • 8. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers.
    Konishi H, Takahashi T, Kozaki K, Yatabe Y, Mitsudomi T, Fujii Y, Sugiura T, Matsuda H, Takahashi T, Takahashi T.
    Oncogene; 1998 Oct 22; 17(16):2095-100. PubMed ID: 9798680
    [Abstract] [Full Text] [Related]

  • 9. A region close to Tp53 shows LOH in familial breast cancer.
    Luo L, Chen J, Du Q, Dumanski J, Blennow E, Kockum I, Luthman H, Lindblom A.
    Int J Mol Med; 2002 Apr 22; 9(4):405-9. PubMed ID: 11891537
    [Abstract] [Full Text] [Related]

  • 10. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
    Seitz S, Poppe K, Fischer J, Nothnagel A, Estévez-Schwarz L, Haensch W, Schlag PM, Scherneck S.
    J Pathol; 2001 Jul 22; 194(3):318-26. PubMed ID: 11439364
    [Abstract] [Full Text] [Related]

  • 11. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus.
    Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M, Yokota J.
    Cancer Res; 1991 Oct 15; 51(20):5632-5. PubMed ID: 1913680
    [Abstract] [Full Text] [Related]

  • 12. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
    Thorlacius S, Börresen AL, Eyfjörd JE.
    Cancer Res; 1993 Apr 01; 53(7):1637-41. PubMed ID: 8453635
    [Abstract] [Full Text] [Related]

  • 13. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas.
    Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, Ikenaga M, Kotoura Y, Sasaki MS.
    Anticancer Res; 1996 Apr 01; 16(4A):2009-15. PubMed ID: 8712735
    [Abstract] [Full Text] [Related]

  • 14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.
    Cancer Res; 2009 Apr 15; 69(8):3625-33. PubMed ID: 19336573
    [Abstract] [Full Text] [Related]

  • 15. The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer.
    Götte K, Riedel F, Neubauer J, Schäfer C, Coy JF, Hörmann K.
    Int J Oncol; 2001 Aug 15; 19(2):331-6. PubMed ID: 11445847
    [Abstract] [Full Text] [Related]

  • 16. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.
    Cancer Res; 2001 Mar 15; 61(6):2505-12. PubMed ID: 11289122
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Allelotype analysis of esophageal squamous cell carcinoma.
    Shibagaki I, Shimada Y, Wagata T, Ikenaga M, Imamura M, Ishizaki K.
    Cancer Res; 1994 Jun 01; 54(11):2996-3000. PubMed ID: 8187088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.